GENEVA, May 6 (Reuters) - The International Federation of Pharmaceutical Manufacturers and Associations said on Wednesday that U.S. President Joe Biden s support for waiving patents of COVID-19 vaccines was the wrong answer to a complex problem and called for more technology transfer agreements.
The Geneva-based IFPMA, which represents research-based pharmaceutical companies, said in a statement: Waiving patents of COVID-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis. On the contrary, it is likely to lead to disruption.
The real challenges are trade barriers, bottlenecks in supply chains, scarcity of raw materials, and willingness by rich countries to start sharing doses with poor countries , it said. (Reporting by Stephanie Nebehay Editing by Chris Reese)
Developing countries are dealing with a shortage of coronavirus vaccines, with the hoarding of supply and the protection of intellectual property in affluent nations two reasons why.
Trade barriers ‘block global COVID-19 vaccine goals’
South African President Cyril Ramaphosa in March 2021 on a visit to the Aspen Pharmacare sterile manufacturing facility in the country s eastern province. Copyright: GCIS. (CC BY-ND 2.0). This photo has been cropped.
Speed read
Nearly 10 billion doses are needed by March 2022 to stem pandemic - World Bank
WHO proposes ‘technology transfer hubs’ to scale up manufacturing in global South
Share this article:
Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
You have to credit our authors.
Pfizer acquires Amplyx Pharmaceuticals, including new potential class of therapeutics
Drug could treat life-threatening antifungal-resistant infections
Pfizer has announced its acquisition of Amplyx Pharmaceuticals, gaining a phase 2 investigational asset for the treatment of invasive fungal infections in the process.
The drug – fosmanogepix – is currently in phase 2 clinical trials evaluating the safety and efficacy of intravenous and oral formulations of the treatment for patients with life-threatening invasive fungal infections caused by molds, yeasts and rare molds.
Pfizer said that fosmanogepix offers a new potential class of therapeutics for the treatment of fungal infections that have become resistant of typical antifungal medications.
India wants access to cheap copies of Covid vaccines So why is Australia holding out? msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.